Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Ability to use the tranplanted limb in activities of daily living at 18 months following transplantation measured by a quantitative functional test.
研究概览
简要总结
The purpose of this study is to determine the safety and efficacy of hand transplantation as a treatment for patients with loss of limb below the elbow, The study will focus on patients who have had loss of limb. The primary endpoint is the ability to use the tranplanted limb in activities of daily living at 18 months following transplantation measured by a quantitative functional test.
Study activities include several study visits over 18 months and include; demographics, medical history, vital signs, psychosocial evaluation, urine, blood test, chest x-ray, bone density scans, and biopsies. Subjects who are 18-65 and willing to travel to site and have loss of limb will be included in study evaluation.
Risks of the study include risk of rejection and infection after being transplanted. Additional risk are associated with procedures that include blood draws, biopsies, x-rays, and potential loss of confidentiality. All patient data will be kept electronically and in accordance with the requirements of Duke University. In addition to the experimental data, this database includes recipient and donor demographics and transplant relevant medical history, range of motion, sensation, and immunosuppressive medications. Data will be recorded and reported in accordance with the standards required by the United Network for Organ Sharing (UNOS).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients from 18-65 years old with loss of limb
- •Willingness and legal ability to give informed consent
- •Willingness to travel to study site for protocol specific samples to be taken, or in some cases, the ability to send samples via overnight mail
排除标准
- •Any condition that precludes serial follow-up
- •Any condition that would likely increase the risk of protocol participation or confound the interpretation of the data
- •Any active malignancy or any history of a malignancy or lymphoma
- •Inability or unwillingness to comply with protocol monitoring and therapy and immunodeficiency syndrome(s)
研究组 & 干预措施
Hand transplant with Belatacept
干预措施: Belatacept (Drug)
Hand transplant with Belatacept
干预措施: Hand transplant (Procedure)
结局指标
主要结局
Ability to use the tranplanted limb in activities of daily living at 18 months following transplantation measured by a quantitative functional test.
时间窗: 18 months
次要结局
- Clinical rejection(18 months)
- Histological rejection(18 months)
研究者
Linda Cendales
Associate Professor of Surgery
Duke University
